These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient. Feldman L; Gabai E; Milovic V; Jaimovich G Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875 [No Abstract] [Full Text] [Related]
26. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110 [TBL] [Abstract][Full Text] [Related]
27. Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation. Nomura S; Konishi A; Tsubokura Y; Azuma Y; Hotta M; Yoshimura H; Nakanishi T; Fujita S; Satake A; Katayama Y; Ohta S; Hayashi K; Ishii K; Ito T Transpl Immunol; 2019 Dec; 57():101247. PubMed ID: 31666188 [TBL] [Abstract][Full Text] [Related]
28. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Song KW; Lipton J Bone Marrow Transplant; 2005 Aug; 36(3):183-91. PubMed ID: 15937497 [TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG). Soyer N; Gunduz M; Tekgunduz E; Deveci B; Ozdogu H; Sahin HH; Turak EE; Okay M; Kuku I; Hindilerden IY; Topcuoglu P; Altuntas F; Karadogan I; Pehlivan M; Unal A; Goker H; Erkurt MA; Besısık SK; Vural F; Transfus Apher Sci; 2020 Aug; 59(4):102827. PubMed ID: 32522474 [TBL] [Abstract][Full Text] [Related]
30. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO; Wilmot F; McCarthy PL; Hahn T Biol Blood Marrow Transplant; 2007 Jan; 13(1):1-25. PubMed ID: 17222748 [TBL] [Abstract][Full Text] [Related]
31. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. Ohshiro M; Kuroda J; Kobayashi Y; Akaogi T; Kawata E; Uoshima N; Kamitsuji Y; Kaneko H; Shimura K; Shimazaki C; Murakami S; Hatsuse M; Okano A; Kobayashi T; Uchiyama H; Matsumoto Y; Horiike S; Taniwaki M Am J Hematol; 2012 Jan; 87(1):116-9. PubMed ID: 21989545 [No Abstract] [Full Text] [Related]
32. [Non-myeloablative allogeneic stem cell transplantation]. Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982 [TBL] [Abstract][Full Text] [Related]
33. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Weber M; Kröger N; Langer F; Hansen A; Zabelina T; Eifrig B; Hossfeld DK; Zander AR Bone Marrow Transplant; 2003 May; 31(9):817-22. PubMed ID: 12732891 [TBL] [Abstract][Full Text] [Related]
34. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Maruyama I Thromb Haemost; 1999 Aug; 82(2):718-21. PubMed ID: 10605773 [No Abstract] [Full Text] [Related]
35. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Kassim AA; Chinratanalab W; Ferrara JL; Mineishi S Bone Marrow Transplant; 2005 Oct; 36(7):565-74. PubMed ID: 15995714 [TBL] [Abstract][Full Text] [Related]
36. Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Inoue Y; Kosugi S; Miura I; Hatta Y; Takeuchi J Thromb Res; 2011 Jun; 127(6):603-4. PubMed ID: 21262525 [No Abstract] [Full Text] [Related]
37. [The effect of the recombinant thrombomodulin which merged to hematological malignancy]. Kawasugi K Rinsho Byori; 2011 Feb; Suppl 147():181-7. PubMed ID: 21761769 [No Abstract] [Full Text] [Related]
38. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. de Lima M; Giralt S Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044 [TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142 [TBL] [Abstract][Full Text] [Related]
40. Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Ho V; Momtaz P; Didas C; Wadleigh M; Richardson P Rev Clin Exp Hematol; 2004 Jun; 8(1):E3. PubMed ID: 16029969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]